nach oben

Current Oncology Reports

Erschienen in:

01.08.2017 | Cardio-oncology (EH Yang, Section Editor)

Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

verfasst von: Gina Biasillo, Carlo M. Cipolla, Daniela Cardinale

Erschienen in: Current Oncology Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Over the past 20 years, cancer treatments have become more effective, leading to significant improvements in survival rates. However, anticancer drugs can have several possible cardiovascular side effects; in particular, the development of left ventricular dysfunction with chemoradiation therapy can negatively affect patients’ cardiac outcome, and can limit anticancer treatments. This is an ongoing issue that will continue to persist, due to the ongoing development of new antitumor agents with potential cardiotoxic effects, and the prolonged life expectancy of long-term cancer survivors. Thus, the need for cooperation between oncologists and cardiologists in the management of cancer patients has led to the development of a new medical discipline-cardio-oncology—where the issue of cardiotoxicity is a topic of intense interest and research. However, several issues remain—the proper definition and diagnosis of cardiotoxicity, as well as monitoring and treatment strategies. In this review, the current advances in cardio-oncology, limitations of current approaches, and future research fields will be discussed.

DeSantis C, Lin C, Mariotto A, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014;64:252–71.CrossRefPubMed

Cardinale D. A new frontier: cardioncology. Cardiologia. 1996;41:887–91.PubMed

Plana JC, Galderisi M, Barac, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.CrossRefPubMedPubMedCentral

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–01.CrossRefPubMed

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.CrossRefPubMed

Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep. 2016;18:51.CrossRefPubMed

•• Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223–35. A complete review on strength and weakness points for the use of biomarkers in the detection of cardiotoxicity CrossRefPubMed

Colombo A, Sandri MT, Salvatici M, Cipolla CM, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16:313.CrossRefPubMed

• Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25. A complete overview on incidence, detection, prevention, management, and clinical impact of cardiotoxicity CrossRefPubMed

10.

Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641–8.CrossRefPubMed

11.

Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–22.CrossRefPubMed

12.

Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710–5.CrossRefPubMed

13.

Auner HW, Tinchon C, Brezinschek RI, Eibl M, Sormann S, Maizen C, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol. 2002;69:1–6.CrossRefPubMed

14.

Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248–52.CrossRefPubMed

15.

Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–54.CrossRefPubMed

16.

Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. Monitoring of cardiac function on the basis of serum troponin levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145:212–20.CrossRefPubMed

17.

Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16:798–804.CrossRefPubMed

18.

Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriuretic peptide and anthracycline-induced cardiac toxicity. Cancer Res Treat. 2008;40:121–6.CrossRefPubMedPubMedCentral

19.

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–6.CrossRefPubMed

20.

Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemo-therapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17:3490–9.CrossRefPubMed

21.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.CrossRefPubMedPubMedCentral

22.

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042–9.CrossRefPubMedPubMedCentral

23.

• Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596–603. This study suggests that the combination of biomarker assessment and the newest echocardiographic techniques may have a greater value in the prediction of cardiotoxicity CrossRefPubMedPubMedCentral

24.

Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, et al. Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. Onkologie. 2012;35:241–6.CrossRefPubMed

25.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–85.CrossRefPubMedPubMedCentral

26.

Mornoş C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol. 2013;91:601–7.CrossRefPubMed

27.

Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013;14:562–9.CrossRefPubMed

28.

Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag I, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809–16.CrossRefPubMed

29.

Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61:1164–72.CrossRefPubMedPubMedCentral

30.

Salvatici M, Cardinale D, Botteri E, Bagnardi V, Mauro C, Cassatella MC, et al. TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. Scand J Clin Lab Invest. 2014;74:385–91.CrossRefPubMed

31.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23:vii155–vii166.

32.

Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197–202.PubMed

33.

Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.CrossRefPubMed

34.

Knobloch K, Tepe J, Lichtinghagen R, Luck HJ, Vogt PM. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol. 2008;125:113–5.CrossRefPubMed

35.

Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011;105:1663–8.CrossRefPubMedPubMedCentral

36.

Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318–26.CrossRefPubMed

37.

Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–44.CrossRefPubMed

38.

Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: systematic review. J Am Coll Cardiol. 2014;63:2751–68.CrossRefPubMed

39.

Vergaro G, Del Franco A, Giannoni A, Prontera C, Ripoli A, Barison A, et al. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol. 2015;184:96–100.CrossRefPubMed

40.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.CrossRefPubMed

41.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.CrossRefPubMed

42.

Fazio S, Calmieri EA, Ferravate B, Bone F, Biondi B, Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998;21:777–9.CrossRefPubMed

43.

Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6:115–9.PubMed

44.

Mukai Y, Yoshida T, Nakaike R, Mukai N, Iwato K, Kyo T, et al. Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med. 2004;43:1087–8.CrossRefPubMed

45.

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–20.CrossRefPubMed

46.

Hopper I, Samuel R, Hayward C, Tonkin A, Krum H. Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis. J Card Fail. 2014;20:522–32.CrossRefPubMed

47.

Shukla A, Yusuf SW, Lenihan D, Durand J. Abstract 2942: high mortality rates are associated with withdrawal of beta blockers and ace inhibitors in chemotherapy-induced heart failure. Circulation. 2008;118:S797.CrossRef

48.

Fadol AP, Banchs J, Hassan SA, Yeh ET, Fellman B. Withdrawal of heart failure medications in cancer survivors with chemotherapy-induced left ventricular dysfunction: a pilot study. J Card Fail. 2016;22:481–2.CrossRefPubMed

49.

Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. 2012;17:160–6.CrossRefPubMed

50.

FDA statement on Dexrazoxane. www.fda.gov/ Drugs/DrugSafety/ucm263729.htm.

51.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.CrossRefPubMed

52.

Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6:420–6.CrossRefPubMed

53.

Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167:2306–10.CrossRefPubMed

54.

Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ 3rd, Cunningham JN Jr, et al. Simultaneous angiotensin-converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–6.CrossRefPubMed

55.

Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492–8.CrossRefPubMed

56.

Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487.e1–7.CrossRef

57.

Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17:81–9.CrossRefPubMed

58.

Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988–9.CrossRefPubMed

59.

Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–90.CrossRefPubMed

60.

Chotenimitkhun R, D’Agostino R Jr, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31:302e–7a.CrossRef

61.

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.CrossRefPubMed

62.

Ederhy S, Massard C, Dufaitre G, Balheda R, Meuleman C, Rocca CG, et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase 1 trials. Investig New Drugs. 2010;30:611–5.CrossRef

Titel: Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts
verfasst von: Gina Biasillo
Carlo M. Cipolla
Daniela Cardinale
Publikationsdatum: 01.08.2017
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 8/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-017-0610-9

Springer Medizin

Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data

Current Management Strategy for Penile Cancer and Future Directions

The Role of Telemedicine in Providing Thoracic Oncology Care to Remote Areas of British Columbia

Early Cervical Cancer: Current Dilemmas of Staging and Surgery

Tumor Treating Fields in Neuro-Oncological Practice

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie